{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T11:00:47Z","timestamp":1769079647610,"version":"3.49.0"},"reference-count":35,"publisher":"Wiley","issue":"20","license":[{"start":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T00:00:00Z","timestamp":1375142400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2013,10,15]]},"abstract":"<jats:sec><jats:title>BACKGROUND<\/jats:title><jats:p>Burkitt lymphoma (BL) is an aggressive but potentially curable lymphoma, previously described in small, single\u2010institution studies. This study evaluated prognostic factors for survival in adult patients with BL and a potential outcome improvement over the past decade in a population\u2010based cohort.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS<\/jats:title><jats:p>Adult patients with BL diagnosed between 1998 and 2009 were selected from the Surveillance, Epidemiology, and End Results (SEER) database. Prognostic factors were identified in a multivariate model for relative survival (RS), and trends in survival were evaluated using period analysis.<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS<\/jats:title><jats:p>The study cohort included 2284 patients, with a median age of 49 years and male predominance (2.6:1). Gastrointestinal tract and the head and neck were the most common sites of extranodal disease. Older age, black race\/ethnicity, and advanced stage were associated with a worse survival. In the period analysis, trends in improved survival between 1998 and 2009 were seen, except for patients older than 60 years and black patients, whose survival did not improve. A prognostic score divided patients into 4 groups: low\u2010risk (5\u2010year RS: 71%), low\u2010intermediate (5\u2010year RS: 55%), high\u2010intermediate (5\u2010year RS: 41%), and high\u2010risk (5\u2010year RS: 29%; <jats:italic>P<\/jats:italic> \u2009&lt;\u2009.001).<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS<\/jats:title><jats:p>The outcome of patients younger than 60 years with BL improved over the past decade. Age, race, and stage have a prognostic role for survival. The proposed score can help inform prognosis in newly diagnosed patients and stratify participants in future trials. <jats:bold><jats:italic>Cancer<\/jats:italic> 2013;119:3672\u20133679<\/jats:bold>. \u00a9 <jats:italic>2013 American Cancer Society<\/jats:italic>.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.28264","type":"journal-article","created":{"date-parts":[[2013,7,30]],"date-time":"2013-07-30T10:26:13Z","timestamp":1375179973000},"page":"3672-3679","source":"Crossref","is-referenced-by-count":60,"title":["Population\u2010based prognostic factors for survival in patients with Burkitt lymphoma: An analysis from the Surveillance, Epidemiology, and End Results database"],"prefix":"10.1002","volume":"119","author":[{"given":"Jorge J.","family":"Castillo","sequence":"first","affiliation":[{"name":"Division of Hematology and Oncology Alpert Medical School of Brown University Rhode Island Hospital\/The Miriam Hospital Providence Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric S.","family":"Winer","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Alpert Medical School of Brown University Rhode Island Hospital\/The Miriam Hospital Providence Rhode Island"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Adam J.","family":"Olszewski","sequence":"additional","affiliation":[{"name":"Division of Hematology and Oncology Alpert Medical School of Brown University Memorial Hospital of Rhode Island Pawtucket RI"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,7,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-02-0405"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-03-145128"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdf253"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.10365"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1986.4.6.847"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V63.5.1102.1102"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdq677"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21776"},{"key":"e_1_2_7_10_1","unstructured":"Surveillance Epidemiology and End Results (SEER) Program(www.seer.cancer.gov) SEER*Stat Database: Incidence \u2010 SEER 18 Regs Research Data + Hurricane Katrina Impacted Louisiana Cases Nov 2011 Sub (1973\u20132009 varying) \u2010 Linked To County Attributes \u2010 Total U.S. 1969\u20132010 Counties National Cancer Institute DCCPS Surveillance Research Program Surveillance Systems Branch released April 2012 based on the November 2011 submission;2012."},{"key":"e_1_2_7_11_1","unstructured":"Surveillance Research Program National Cancer Institute SEER*Stat software version 8.0.2;2013."},{"key":"e_1_2_7_12_1","unstructured":"NAACCR Race and Ethnicity Work Group.NAACCR Guideline for Enhancing Hispanic\/Latino Identification: Revised NAACCR Hispanic\/Latino Identification Algorithm [NHIA v2.2.1].http:\/\/www.naaccr.org\/LinkClick.aspx?fileticket=6E20OT41TcA%3dRevised September 12 2011. Accessed April 26 2012."},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2011.03.011"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1002\/sim.3064"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10552-012-0141-5"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0258(20000715)19:13<1729::AID-SIM484>3.0.CO;2-9"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-11-96"},{"key":"e_1_2_7_18_1","unstructured":"CroninK MariottoA ScoppaS GreenD CleggL.Differences Between Brenner et al. and NCI Methods for Calculating Period Survival. Technical Report 2003\u201302. Statistical Research and Applications Branch National Cancer Institute [serial online]2003.http:\/\/surveillance.cancer.gov\/reports. Accessed February 19 2013."},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2003.10.013"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.05.1003"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(06)70664-7"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-03-276246"},{"key":"e_1_2_7_23_1","doi-asserted-by":"crossref","unstructured":"RibragV KoscielnyS BouabdallahK et al.Addition of Rituximab Improves Outcome of HIV Negative Patients with Burkitt Lymphoma Treated with the Lmba Protocol: Results of the Randomized Intergroup (GRAALL\u2010Lysa) LMBA02 Protocol. (IGR sponsored LMBA02 NCT00180882). American Society of Hematology Annual Meeting Abstracts.2012;120: Abstract 685.","DOI":"10.1182\/blood.V120.21.685.685"},{"key":"e_1_2_7_24_1","doi-asserted-by":"crossref","unstructured":"EvensAM IslamN CarsonKR et al.A phase 2 clinical trial adding rituximab to CODOX\u2010M\/IVAC for untreated Burkitts lymphoma: correlative analysis of serum and CSF rituximab levels. American Society of Hematology Annual Meeting Abstracts.2012;120: Abstract 1640.","DOI":"10.1182\/blood.V120.21.1640.1640"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2009.n.060"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04134.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25765"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-12-0466"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1155\/2010\/824691"},{"key":"e_1_2_7_30_1","first-page":"1881","article-title":"Disparities in survival after Hodgkin lymphoma: a population\u2010based study","volume":"20","author":"Keegan TH","year":"2009","journal-title":"Cancer CausesControl."},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-12-475558"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-03-0250"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1158\/1055-9965.EPI-05-0549"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2011.593274"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.23522"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/735392"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.28264","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.28264","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T08:47:43Z","timestamp":1760258863000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.28264"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7,30]]},"references-count":35,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2013,10,15]]}},"alternative-id":["10.1002\/cncr.28264"],"URL":"https:\/\/doi.org\/10.1002\/cncr.28264","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,7,30]]}}}